The evidence base of the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents
Objective. To carry out a systematic analysis of the data available in modern Russian and foreign literature on the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents, such as Ovipol Clio.Chilova R.A., Chushkov Yu.V., Proklova G.F.
Material and methods. The review includes the data of foreign and Russian articles published in the past 10 years and found in the Pubmed on this topic. Particular attention is given to the 2015-2017 articles.
Results. The paper describes the evidence base of the efficiency and safety of estriol-containing intravaginal drugs, such as Ovipol Clio, in the treatment of menopausal syndrome. Analyzing the literature has clearly shown that the use of Ovipol Clio causes a significant reduction in menopausal symptoms and an improvement of a woman’s urogenital health. In this case, the earlier the treatment is initiated after the onset of menopause, the lower risk of menopause-associated pathological conditions.
Conclusion. Additional studies on the safety and efficiency of transvaginal estriol deserve further examination.
Keywords
menopause
menopausal syndrome
Ovipol Clio
hormone replacement therapy
References
1. Балан В.Е. Вагинальная атрофия в климактерии: лекция. Эффективная фармакотерапия в акушерстве и гинекологии. 2009; 3: 40-3. [Balan V.E. Vaginal atrophy in menopause: lecture. Effective pharmacotherapy in obstetrics and gynecology. 2009; 3: 40-3. (in Russian)]
2. Занько С.Н., Радецкая Л.Е. Заместительная гормональная терапия: дифференцированный подход. Методическое пособие. Минск: Доктор Дизайн; 2008: 25. [Zanko S.N., Radetska L.E. Hormone replacement therapy: a differentiated approach. Toolkit. Minsk: Doctor Design; 2008: 25. (in Russian)]
3. Сметник В.П. Медико-социальные проблемы климактерия. В кн.: Кулаков В.И., Демидова Е.М., ред. Гормональная коррекция системных изменений в менопаузе. Материалы симпозиума. М.; 1997: 7-14. [Smetnik V.P. Medico-social problems of menopause. In: Kulakov V.I., Demidova E.M., ed. Hormonal correction of systemic changes in menopause. Materials of the symposium. Moscow; 1997: 7-14. (in Russian)]
4. Шаповаленко С.А. Комплексная терапия психосоматических расстройств в перименопаузальный период. Вестник Российской ассоциации акушеров и гинекологов. 2000; 1: 91-5. [Shapovalenko S.A. Complex therapy of psychosomatic disorders in the perimenopausal period. Bulletin of the Russian Association of Obstetricians and Gynecologists. 2000; 1: 91-5. (in Russian)]
5. Репина М.А. Выпадение функции яичников и заместительное гормональное лечение. Журнал акушерства и женских болезней. 1999; 67(1): 72-6. [Repina M.A. Abnormal ovarian function and hormone replacement therapy. Zhurnal akusherstva i zhenskih bolezney. 1999; 67 (1): 72-6. (in Russian)]
6. Crandall C.J., Hovey K.M., Andrews C.A., Chlebowski R.T., Stefanick M.L., Lane D.S. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2017; August 14. doi: 10.1097/GME.0000000000000956.
7. Ali E.S., Mangold C., Peiris A.N. Estriol: emerging clinical benefits Menopause. 2017; 24(9): 1081-5. doi: 10.1097/GME.0000000000000855.
8. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7): 728-53. doi: 10.1097/GME.0000000000000921.
9. Cruz V.L., Steiner M.L., Pompei L.M., Strufaldi R., Fonseca F.L.A., Santiago L.H.S. et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2017; July 31. doi: 10.1097/GME.0000000000000955.
10. Hodis H.N., Mack W.J., Shoupe D., Azen S.P., Stanczyk F.Z., Hwang-Levine J. et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015; 22(4): 391-401. doi: 10.1097/GME.0000000000000343.
Received 13.10.2017
Accepted 27.10.2017
About the Authors
Chilova Raisa Alekseevna, MD, Professor of the Department of Obstetrics and Gynecology No. 1, I.M. Sechenov First Moscow State Medical University,Ministry of Health of Russia; doctor obstetrician-gynecologist, V.F. Snegirev Clinic of Obstetrics and Gynecology. 119991, Russia, Moscow, Trubetskaya str. 8, bld. 2
Chushkov Yuri Vasilievich, MD, associate professor of the Department of Obstetrics and Gynecology No. 1, I.M. Sechenov First Moscow State Medical University,
Ministry of Health of Russia. 119991, Russia, Moscow, Trubetskaya str. 8, bld. 2. Tel.: +79266191566. E-mail: yury-chushkov@rambler.ru
Proklova Guzel Faritovna, laboratory assistant of the Department of Obstetrics and Gynecology No. 1, I.M. Sechenov First Moscow State Medical University,
Ministry of Health of Russia; doctor obstetrician-gynecologist, V.F. Snegirev Clinic of Obstetrics and Gynecology. 119991, Russia, Moscow, Trubetskaya str. 8, bld. 2
For citations: Chilova R.A., Chushkov Yu.V., Proklova G.F. The evidence base of the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (12): 126-30. (in Russian)
https://dx.doi.org/10.18565/aig.2017.12.126-130
Similar Articles
